Councilor: Kevin K.W. Wang

文章附图
  • Kevin K.W. Wang, Ph.D.

  • Department of Psychiatry, University of Florida, McKnight Brain Institute, Gainesville, FL, USA

  • http://nnbr.mbi.ufl.edu/

  • Dr. Wang obtained his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia in Vancouver. He is internationally recognized for his original contributions to the fields of CNS disorders-linked proteolytic enzymes, neuroproteomics and disease biomarker discovery. He joined Parke-Davis Pharmaceutical Research (Ann Arbor, MI) in 1991, and then Pfizer Inc. following its merger with Parke-Davis (2000), where he became Group Leader of CNS Therapeutics/CNS new targets team. He became Associate Professor of Psychiatry at the University of Florida (Gainesville, FL) and Associate Director of the Center for Traumatic Brain Injury Studies. In 2002, he co-founded Banyan Biomarkers Inc. (Alachua, Florida) towards the development of blood-based diagnostics for mild traumatic brain injury/concussions. In 2007, he transitioned to Banyan as full-time Chief Scientific Officer and Director of the Center of Innovative Research. In 2011, he rejoined the University of Florida McKnight Brain Institute as Executive Director of the Center for Neuroproteomics and Biomarkers Research & Associate Professor of Psychiatry and Neuroscience to continue his basic and translational research in CNS injuries. He is also Chair Professor of the Taipei Medical University.

  • Dr. Wang published more than 200 peer-reviewed papers, reviews and book chapters and co-authored 12 US and international patents. He co-edited four books on a range of scientific topics including proteases, neuroproteomics and biomarkers for CNS disorders. Dr. Wang is Past President and current Council Member of the National Neurotrauma Society (USA). His research interests include Neuro-Proteomics, CNS Injury, Neurodegeneration, substance abuse research, Post-translational modification (Protease /Protein Kinase) research, Biomarkers, Diagnostics and Therapeutic development.